Acne Vulgaris – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acne Vulgaris – Pipeline Review, H2 2016’, provides an overview of the Acne Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris

The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects

The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acne Vulgaris

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc.

Allergan Plc

Almirall, S.A.

Antibiotx ApS

Biomar Microbial Technologies

BiopharmX, Inc.

Braintree Laboratories, Inc.

Brickell Biotech, Inc.

Cell Medica Limited

Cellceutix Corporation

Celtaxsys, Inc.

Common Pharma Inc

Cutanea Life Sciences Inc

DermaXon, LLC

Dermira Inc.

Diffusion Pharmaceuticals Inc.

ELORAC, Inc.

Ensol Biosciences Inc.

Foamix Pharmaceuticals Ltd.

Galderma S.A.

GlaxoSmithKline Plc

Helix BioMedix, Inc.

Hovione FarmaCiencia SA

Lee's Pharmaceutical Holdings Limited

LEO Pharma A/S

Novabiotics Limited

Novan, Inc.

Paratek Pharmaceuticals, Inc.

Pfizer Inc.

Phosphagenics Limited

Photocure ASA

Promius Pharma, LLC

Provectus Biopharmaceuticals, Inc.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Sol-Gel Technologies Ltd.

Sun Pharma Advanced Research Company Ltd.

Telesso Technologies Limited

Thesan Pharmaceuticals, Inc.

Valeant Pharmaceuticals International, Inc.

Vectura Group Plc

Vyome Biosciences Private Limited

XBiotech Inc

Xenon Pharmaceuticals Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acne Vulgaris Overview 9

Therapeutics Development 10

Pipeline Products for Acne Vulgaris - Overview 10

Pipeline Products for Acne Vulgaris - Comparative Analysis 11

Acne Vulgaris - Therapeutics under Development by Companies 12

Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes 15

Acne Vulgaris - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Acne Vulgaris - Products under Development by Companies 19

Acne Vulgaris - Products under Investigation by Universities/Institutes 23

Acne Vulgaris - Companies Involved in Therapeutics Development 24

3SBio Inc. 24

Allergan Plc 25

Almirall, S.A. 26

Antibiotx ApS 27

Biomar Microbial Technologies 28

BiopharmX, Inc. 29

Braintree Laboratories, Inc. 30

Brickell Biotech, Inc. 31

Cell Medica Limited 32

Cellceutix Corporation 33

Celtaxsys, Inc. 34

Common Pharma Inc 35

Cutanea Life Sciences Inc 36

DermaXon, LLC 37

Dermira Inc. 38

Diffusion Pharmaceuticals Inc. 39

ELORAC, Inc. 40

Ensol Biosciences Inc. 41

Foamix Pharmaceuticals Ltd. 42

Galderma S.A. 43

GlaxoSmithKline Plc 44

Helix BioMedix, Inc. 45

Hovione FarmaCiencia SA 46

Lee's Pharmaceutical Holdings Limited 47

LEO Pharma A/S 48

Novabiotics Limited 49

Novan, Inc. 50

Paratek Pharmaceuticals, Inc. 51

Pfizer Inc. 52

Phosphagenics Limited 53

Photocure ASA 54

Promius Pharma, LLC 55

Provectus Biopharmaceuticals, Inc. 56

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 57

Sol-Gel Technologies Ltd. 58

Sun Pharma Advanced Research Company Ltd. 59

Telesso Technologies Limited 60

Thesan Pharmaceuticals, Inc. 61

Valeant Pharmaceuticals International, Inc. 62

Vectura Group Plc 63

Vyome Biosciences Private Limited 64

XBiotech Inc 65

Xenon Pharmaceuticals Inc. 66

Acne Vulgaris - Therapeutics Assessment 67

Assessment by Monotherapy Products 67

Assessment by Combination Products 68

Assessment by Target 69

Assessment by Mechanism of Action 72

Assessment by Route of Administration 75

Assessment by Molecule Type 77

Drug Profiles 79

(adapalene + clindamycin hydrochloride) - Drug Profile 79

(benzoyl peroxide + tretinoin) - Drug Profile 80

(clindamycin phosphate + tretinoin) - Drug Profile 81

A-3APO - Drug Profile 82

acebilustat - Drug Profile 83

Aczone Combo - Drug Profile 86

Aczone X - Drug Profile 87

aminolevulinic acid hydrochloride - Drug Profile 88

AQ-401 - Drug Profile 89

ATx-202 - Drug Profile 90

B-244 - Drug Profile 91

BBI-3000 - Drug Profile 92

benzoyl peroxide - Drug Profile 93

BLI-1100 - Drug Profile 94

botulinum toxinA - Drug Profile 95

brilacidin tetrahydrochloride - Drug Profile 96

CB-0301 - Drug Profile 105

CB-0601 - Drug Profile 108

CLS-007 - Drug Profile 109

dapsone - Drug Profile 110

DFD-10 - Drug Profile 111

DLX-2323 - Drug Profile 112

DLX-2681 - Drug Profile 113

DMT-210 - Drug Profile 114

DRM-01 - Drug Profile 115

DX-0385 - Drug Profile 118

E-10215 - Drug Profile 119

finasteride - Drug Profile 120

FMX-101 - Drug Profile 121

GSK-1940029 - Drug Profile 124

HB-1345 - Drug Profile 125

Hesed-4000 - Drug Profile 126

IB-07A037 - Drug Profile 127

IDP-120 - Drug Profile 128

IDP-121 - Drug Profile 129

IDP-123 - Drug Profile 130

IDP-126 - Drug Profile 131

IDP-129 - Drug Profile 132

IDP-130 - Drug Profile 133

ivermectin - Drug Profile 134

LEO-43204 - Drug Profile 135

LTA-001 - Drug Profile 136

methyl aminolevulinate hydrochloride - Drug Profile 137

minocycline - Drug Profile 139

minocycline - Drug Profile 140

minocycline hydrochloride - Drug Profile 142

MTC-896 - Drug Profile 143

omiganan pentahydrochloride - Drug Profile 144

Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 146

PF-06423264 - Drug Profile 147

PH-10 - Drug Profile 148

RA-18C3 - Drug Profile 151

RES-440 - Drug Profile 153

sarecycline hydrochloride - Drug Profile 155

SB-204 - Drug Profile 157

SKP-026 - Drug Profile 160

Small Molecule for Acne and Skin Inflammation - Drug Profile 161

Small Molecules for Acne Vulgaris - Drug Profile 162

Synthetic Peptide for Acne Vulgaris - Drug Profile 163

Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile 164

tazarotene - Drug Profile 165

tretinoin - Drug Profile 166

tretinoin - Drug Profile 167

trifarotene - Drug Profile 168

TSN-2898 - Drug Profile 170

Vaccine for Acne Vulgaris - Drug Profile 171

VB-1953 - Drug Profile 172

XEN-801 - Drug Profile 173

Acne Vulgaris - Dormant Projects 174

Acne Vulgaris - Discontinued Products 181

Acne Vulgaris - Product Development Milestones 182

Featured News & Press Releases 182

Appendix 194

Methodology 194

Coverage 194

Secondary Research 194

Primary Research 194

Expert Panel Validation 194

Contact Us 194

Disclaimer 195

List of Tables

List of Tables

Number of Products under Development for Acne Vulgaris, H2 2016 15

Number of Products under Development for Acne Vulgaris – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Development by Companies, H2 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Development by Companies, H2 2016 (Contd..3) 27

Products under Investigation by Universities/Institutes, H2 2016 28

Acne Vulgaris – Pipeline by 3SBio Inc., H2 2016 29

Acne Vulgaris – Pipeline by Allergan Plc, H2 2016 30

Acne Vulgaris – Pipeline by Almirall, S.A., H2 2016 31

Acne Vulgaris – Pipeline by Antibiotx ApS, H2 2016 32

Acne Vulgaris – Pipeline by Biomar Microbial Technologies, H2 2016 33

Acne Vulgaris – Pipeline by BiopharmX, Inc., H2 2016 34

Acne Vulgaris – Pipeline by Braintree Laboratories, Inc., H2 2016 35

Acne Vulgaris – Pipeline by Brickell Biotech, Inc., H2 2016 36

Acne Vulgaris – Pipeline by Cell Medica Limited, H2 2016 37

Acne Vulgaris – Pipeline by Cellceutix Corporation, H2 2016 38

Acne Vulgaris – Pipeline by Celtaxsys, Inc., H2 2016 39

Acne Vulgaris – Pipeline by Common Pharma Inc, H2 2016 40

Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, H2 2016 41

Acne Vulgaris – Pipeline by DermaXon, LLC, H2 2016 42

Acne Vulgaris – Pipeline by Dermira Inc., H2 2016 43

Acne Vulgaris – Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 44

Acne Vulgaris – Pipeline by ELORAC, Inc., H2 2016 45

Acne Vulgaris – Pipeline by Ensol Biosciences Inc., H2 2016 46

Acne Vulgaris – Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 47

Acne Vulgaris – Pipeline by Galderma S.A., H2 2016 48

Acne Vulgaris – Pipeline by GlaxoSmithKline Plc, H2 2016 49

Acne Vulgaris – Pipeline by Helix BioMedix, Inc., H2 2016 50

Acne Vulgaris – Pipeline by Hovione FarmaCiencia SA, H2 2016 51

Acne Vulgaris – Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 52

Acne Vulgaris – Pipeline by LEO Pharma A/S, H2 2016 53

Acne Vulgaris – Pipeline by Novabiotics Limited, H2 2016 54

Acne Vulgaris – Pipeline by Novan, Inc., H2 2016 55

Acne Vulgaris – Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 56

Acne Vulgaris – Pipeline by Pfizer Inc., H2 2016 57

Acne Vulgaris – Pipeline by Phosphagenics Limited, H2 2016 58

Acne Vulgaris – Pipeline by Photocure ASA, H2 2016 59

Acne Vulgaris – Pipeline by Promius Pharma, LLC, H2 2016 60

Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 61

Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016 62

Acne Vulgaris – Pipeline by Sol-Gel Technologies Ltd., H2 2016 63

Acne Vulgaris – Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 64

Acne Vulgaris – Pipeline by Telesso Technologies Limited, H2 2016 65

Acne Vulgaris – Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 66

Acne Vulgaris – Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 67

Acne Vulgaris – Pipeline by Vectura Group Plc, H2 2016 68

Acne Vulgaris – Pipeline by Vyome Biosciences Private Limited, H2 2016 69

Acne Vulgaris – Pipeline by XBiotech Inc, H2 2016 70

Acne Vulgaris – Pipeline by Xenon Pharmaceuticals Inc., H2 2016 71

Assessment by Monotherapy Products, H2 2016 72

Assessment by Combination Products, H2 2016 73

Number of Products by Stage and Target, H2 2016 75

Number of Products by Stage and Mechanism of Action, H2 2016 78

Number of Products by Stage and Route of Administration, H2 2016 81

Number of Products by Stage and Molecule Type, H2 2016 83

Acne Vulgaris – Dormant Projects, H2 2016 179

Acne Vulgaris – Dormant Projects (Contd..1), H2 2016 180

Acne Vulgaris – Dormant Projects (Contd..2), H2 2016 181

Acne Vulgaris – Dormant Projects (Contd..3), H2 2016 182

Acne Vulgaris – Dormant Projects (Contd..4), H2 2016 183

Acne Vulgaris – Dormant Projects (Contd..5), H2 2016 184

Acne Vulgaris – Dormant Projects (Contd..6), H2 2016 185

Acne Vulgaris – Discontinued Products, H2 2016 186

List of Figures

List of Figures

Number of Products under Development for Acne Vulgaris, H2 2016 15

Number of Products under Development for Acne Vulgaris – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Late Stage Development, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 22

Comparative Analysis by Early Stage Products, H2 2016 23

Assessment by Monotherapy Products, H2 2016 72

Assessment by Combination Products, H2 2016 73

Number of Products by Top 10 Targets, H2 2016 74

Number of Products by Stage and Top 10 Targets, H2 2016 74

Number of Products by Top 10 Mechanism of Actions, H2 2016 77

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 77

Number of Products by Routes of Administration, H2 2016 80

Number of Products by Stage and Routes of Administration, H2 2016 80

Number of Products by Molecule Types, H2 2016 82

Number of Products by Stage and Molecule Types, H2 2016 82

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports